+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Uveitis Treatment Market, by Drug Class, by Disease Type, by Distribution Channel, by Region, Industry Analysis and Forecast, 2019 - 2025

  • ID: 5017765
  • Report
  • March 2020
  • Region: Global
  • 214 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
The Global Uveitis Treatment Market size is expected to reach $686.1 Million by 2025, rising at a market growth of 5.5% CAGR during the forecast period. Uveitis is the inflammation of the middle tissue layer in the uvea eyewall which consists of the iris, choroid, and ciliary body. Various drug formulations such as anti-inflammatory drugs, cycloplegic agents, antimicrobial drugs, immunotherapy & targeted therapies, and others are used for uveitis treatment. These involve anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Inflammation of the iris called iritis or anterior uveitis is the most prevalent form of uveitis.

Increased prevalence of uveitis and growing awareness among the patient population with increased acceptance of innovative treatments is expected to drive the growth of the market. In addition, convenient access to uveitis treatment, increased demand for uveitis medications, and a boom in R&D activities to improve ideal uveitis treatment to further drive the growth of the industry.

Nevertheless, it is anticipated that the uncertain etiology and pathophysiology of uveitis is expected to hinder market development. In addition, untapped capacity offered by emerging economies is presenting lucrative opportunities for market growth over the forecast period. Nonetheless, there is likely to be a shortage of effective treatment for uveitis disorder to limit the market growth.

Uveitis is considered the leading cause of blindness in the United States, with a steady rise in prevalence. Corticosteroid is considered the first-line treatment for uveitis. A large number of compounds for treating uveitis are lined up in growth. Leading industry players are adding new drugs to improve their product portfolio. The procedure for the sterile formulations, however, is highly complex and businesses are likely to align themselves with the GMP and regulatory requirements for producing their products.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Strategies deployed in Uveitis Treatment Market

Mar-2020: Clearside Biomedical announced an agreement with Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia. Under this agreement, the latter company has acquired an exclusive license for the commercialization and development of XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.

Feb-2020: Santen Pharmaceutical signed an agreement with Verily, an Alphabet company. Following the agreement, the companies is expected to establish a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology.

Oct-2019: Bausch Health Ireland signed an agreement with Clearside Biomedical. The agreement granted Bausch with an exclusive license for developing, manufacturing, distributing, promoting, marketing, and commercializing the suprachoroidal injection device.

Sep-2019: Alimera Sciences launched ILUVIEN in Germany. This solution has been used in prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).

Jul-2019: Novartis completed the acquisition of Xiidra (lifitegrast ophthalmic solution), the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The acquisition enabled the company to deliver medicine for patients suffering from a variety of eye diseases.

Mar-2019: Novartis got FDA approval for Mayzent (siponimod), a new solution for the treatment of relapsing forms of multiple sclerosis (RMS).

Feb-2019: EyePoint Pharmaceuticals released the Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis, which affects the posterior segment of the eye. The company also announced the launch of EyePoint Assist, a program for ensuring access to Yutiq for eligible patients in need of financial assistance.

Oct-2018: Amgen introduced Amgevita in Europe. This therapy is available in the 28 countries of the European Union, plus Norway, Iceland, and Liechtenstein. Amgevita is a human antibody that has been designed for targeting the human tumor necrosis factor alpha (TNFα), an immune factor that regulates the inflammatory response.

Mar-2018: pSivida acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. Following the acquisition, both the companies have combined their businesses and started doing business as EyePoint Pharmaceuticals.

Jul-2016: AbbVie got FDA approval for Humira, a new therapy for non-infectious intermediate, posterior, and panuveitis. This is a non-corticosteroid treatment option for certain types of uveitis, an eye disease that can flare and impact vision.

Scope of the Study

Market Segmentation:

By Drug Class
  • Anti-inflammatory
  • Immunotherapy & Targeted Therapies
  • Antimicrobial Drugs
  • Other Drug Class
By Disease Type
  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online stores
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Uveitis Treatment Market, by Drug Class
1.4.2 Global Uveitis Treatment Market, by Disease Type
1.4.3 Global Uveitis Treatment Market, by Distribution Channel
1.4.4 Global Uveitis Treatment Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Uveitis Treatment Market by Drug Class
3.1 Global Anti-inflammatory Market by Region
3.2 Global Immunotherapy & Targeted Therapies Market by Region
3.3 Global Antimicrobial Drugs Market by Region
3.4 Global Other Drug Class Market by Region

Chapter 4. Global Uveitis Treatment Market by Disease Type
4.1 Global Anterior Uveitis Market by Region
4.2 Global Posterior Uveitis Market by Region
4.3 Global Intermediate Uveitis Market by Region
4.4 Global Other Diseases Market by Region

Chapter 5. Global Uveitis Treatment Market by Distribution Channel
5.1 Global Hospital Pharmacies Market by Region
5.2 Global Retail Pharmacies Market by Region
5.3 Global Online stores Market by Region

Chapter 6. Global Uveitis Treatment Market by Region
6.1 North America Uveitis Treatment Market
6.1.1 North America Uveitis Treatment Market by Drug Class
6.1.1.1 North America Anti-inflammatory Market by Country
6.1.1.2 North America Immunotherapy & Targeted Therapies Market by Country
6.1.1.3 North America Antimicrobial Drugs Market by Country
6.1.1.4 North America Other Drug Class Market by Country
6.1.2 North America Uveitis Treatment Market by Disease Type
6.1.2.1 North America Anterior Uveitis Market by Country
6.1.2.2 North America Posterior Uveitis Market by Country
6.1.2.3 North America Intermediate Uveitis Market by Country
6.1.2.4 North America Other Disease Types Market by Country
6.1.3 North America Uveitis Treatment Market by Distribution Channel
6.1.3.1 North America Hospital Pharmacies Market by Country
6.1.3.2 North America Retail Pharmacies Market by Country
6.1.3.3 North America Online stores Market by Country
6.1.4 North America Uveitis Treatment Market by Country
6.1.4.1 USA Uveitis Treatment Market
6.1.4.1.1 USA Uveitis Treatment Market by Drug Class
6.1.4.1.2 USA Uveitis Treatment Market by Disease Type
6.1.4.1.3 USA Uveitis Treatment Market by Distribution Channel
6.1.4.2 Canada Uveitis Treatment Market
6.1.4.2.1 Canada Uveitis Treatment Market by Drug Class
6.1.4.2.2 Canada Uveitis Treatment Market by Disease Type
6.1.4.2.3 Canada Uveitis Treatment Market by Distribution Channel
6.1.4.3 Mexico Uveitis Treatment Market
6.1.4.3.1 Mexico Uveitis Treatment Market by Drug Class
6.1.4.3.2 Mexico Uveitis Treatment Market by Disease Type
6.1.4.3.3 Mexico Uveitis Treatment Market by Distribution Channel
6.1.4.4 Rest of North America Uveitis Treatment Market
6.1.4.4.1 Rest of North America Uveitis Treatment Market by Drug Class
6.1.4.4.2 Rest of North America Uveitis Treatment Market by Disease Type
6.1.4.4.3 Rest of North America Uveitis Treatment Market by Distribution Channel
6.2 Europe Uveitis Treatment Market
6.2.1 Europe Uveitis Treatment Market by Drug Class
6.2.1.1 Europe Anti-inflammatory Market by Country
6.2.1.2 Europe Immunotherapy & Targeted Therapies Market by Country
6.2.1.3 Europe Antimicrobial Drugs Market by Country
6.2.1.4 Europe Other Drug Class Market by Country
6.2.2 Europe Uveitis Treatment Market by Disease Type
6.2.2.1 Europe Anterior Uveitis Market by Country
6.2.2.2 Europe Posterior Uveitis Market by Country
6.2.2.3 Europe Intermediate Uveitis Market by Country
6.2.2.4 Europe Other Diseases Market by Country
6.2.3 Europe Uveitis Treatment Market by Distribution Channel
6.2.3.1 Europe Hospital Pharmacies Market by Country
6.2.3.2 Europe Retail Pharmacies Market by Country
6.2.3.3 Europe Online stores Market by Country
6.2.4 Europe Uveitis Treatment Market by Country
6.2.4.1 Germany Uveitis Treatment Market
6.2.4.1.1 Germany Uveitis Treatment Market by Drug Class
6.2.4.1.2 Germany Uveitis Treatment Market by Disease Type
6.2.4.1.3 Germany Uveitis Treatment Market by Distribution Channel
6.2.4.2 UK Uveitis Treatment Market
6.2.4.2.1 UK Uveitis Treatment Market by Drug Class
6.2.4.2.2 UK Uveitis Treatment Market by Disease Type
6.2.4.2.3 UK Uveitis Treatment Market by Distribution Channel
6.2.4.3 France Uveitis Treatment Market
6.2.4.3.1 France Uveitis Treatment Market by Drug Class
6.2.4.3.2 France Uveitis Treatment Market by Disease Type
6.2.4.3.3 France Uveitis Treatment Market by Distribution Channel
6.2.4.4 Russia Uveitis Treatment Market
6.2.4.4.1 Russia Uveitis Treatment Market by Drug Class
6.2.4.4.2 Russia Uveitis Treatment Market by Disease Type
6.2.4.4.3 Russia Uveitis Treatment Market by Distribution Channel
6.2.4.5 Spain Uveitis Treatment Market
6.2.4.5.1 Spain Uveitis Treatment Market by Drug Class
6.2.4.5.2 Spain Uveitis Treatment Market by Disease Type
6.2.4.5.3 Spain Uveitis Treatment Market by Distribution Channel
6.2.4.6 Italy Uveitis Treatment Market
6.2.4.6.1 Italy Uveitis Treatment Market by Drug Class
6.2.4.6.2 Italy Uveitis Treatment Market by Disease Type
6.2.4.6.3 Italy Uveitis Treatment Market by Distribution Channel
6.2.4.7 Rest of Europe Uveitis Treatment Market
6.2.4.7.1 Rest of Europe Uveitis Treatment Market by Drug Class
6.2.4.7.2 Rest of Europe Uveitis Treatment Market by Disease Type
6.2.4.7.3 Rest of Europe Uveitis Treatment Market by Distribution Channel
6.3 Asia Pacific Uveitis Treatment Market
6.3.1 Asia Pacific Uveitis Treatment Market by Drug Class
6.3.1.1 Asia Pacific Anti-inflammatory Market by Country
6.3.1.2 Asia Pacific Immunotherapy & Targeted Therapies Market by Country
6.3.1.3 Asia Pacific Antimicrobial Drugs Market by Country
6.3.1.4 Asia Pacific Other Drug Class Market by Country
6.3.2 Asia Pacific Uveitis Treatment Market by Disease Type
6.3.2.1 Asia Pacific Anterior Uveitis Market by Country
6.3.2.2 Asia Pacific Posterior Uveitis Market by Country
6.3.2.3 Asia Pacific Intermediate Uveitis Market by Country
6.3.2.4 Asia Pacific Other Diseases Market by Country
6.3.3 Asia Pacific Uveitis Treatment Market by Distribution Channel
6.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
6.3.3.2 Asia Pacific Retail Pharmacies Market by Country
6.3.3.3 Asia Pacific Online stores Market by Country
6.3.4 Asia Pacific Uveitis Treatment Market by Country
6.3.4.1 China Uveitis Treatment Market
6.3.4.1.1 China Uveitis Treatment Market by Drug Class
6.3.4.1.2 China Uveitis Treatment Market by Disease Type
6.3.4.1.3 China Uveitis Treatment Market by Distribution Channel
6.3.4.2 Japan Uveitis Treatment Market
6.3.4.2.1 Japan Uveitis Treatment Market by Drug Class
6.3.4.2.2 Japan Uveitis Treatment Market by Disease Type
6.3.4.2.3 Japan Uveitis Treatment Market by Distribution Channel
6.3.4.3 India Uveitis Treatment Market
6.3.4.3.1 India Uveitis Treatment Market by Drug Class
6.3.4.3.2 India Uveitis Treatment Market by Disease Type
6.3.4.3.3 India Uveitis Treatment Market by Distribution Channel
6.3.4.4 South Korea Uveitis Treatment Market
6.3.4.4.1 South Korea Uveitis Treatment Market by Drug Class
6.3.4.4.2 South Korea Uveitis Treatment Market by Disease Type
6.3.4.4.3 South Korea Uveitis Treatment Market by Distribution Channel
6.3.4.5 Singapore Uveitis Treatment Market
6.3.4.5.1 Singapore Uveitis Treatment Market by Drug Class
6.3.4.5.2 Singapore Uveitis Treatment Market by Disease Type
6.3.4.5.3 Singapore Uveitis Treatment Market by Distribution Channel
6.3.4.6 Malaysia Uveitis Treatment Market
6.3.4.6.1 Malaysia Uveitis Treatment Market by Drug Class
6.3.4.6.2 Malaysia Uveitis Treatment Market by Disease Type
6.3.4.6.3 Malaysia Uveitis Treatment Market by Distribution Channel
6.3.4.7 Rest of Asia Pacific Uveitis Treatment Market
6.3.4.7.1 Rest of Asia Pacific Uveitis Treatment Market by Drug Class
6.3.4.7.2 Rest of Asia Pacific Uveitis Treatment Market by Disease Type
6.3.4.7.3 Rest of Asia Pacific Uveitis Treatment Market by Distribution Channel
6.4 LAMEA Uveitis Treatment Market
6.4.1 LAMEA Uveitis Treatment Market by Drug Class
6.4.1.1 LAMEA Anti-inflammatory Market by Country
6.4.1.2 LAMEA Immunotherapy & Targeted Therapies Market by Country
6.4.1.3 LAMEA Antimicrobial Drugs Market by Country
6.4.1.4 LAMEA Other Drug Class Market by Country
6.4.2 LAMEA Uveitis Treatment Market by Disease Type
6.4.2.1 LAMEA Anterior Uveitis Market by Country
6.4.2.2 LAMEA Posterior Uveitis Market by Country
6.4.2.3 LAMEA Intermediate Uveitis Market by Country
6.4.2.4 LAMEA Other Diseases Market by Country
6.4.3 LAMEA Uveitis Treatment Market by Distribution Channel
6.4.3.1 LAMEA Hospital Pharmacies Market by Country
6.4.3.2 LAMEA Retail Pharmacies Market by Country
6.4.3.3 LAMEA Online stores Market by Country
6.4.4 LAMEA Uveitis Treatment Market by Country
6.4.4.1 Brazil Uveitis Treatment Market
6.4.4.1.1 Brazil Uveitis Treatment Market by Drug Class
6.4.4.1.2 Brazil Uveitis Treatment Market by Disease Type
6.4.4.1.3 Brazil Uveitis Treatment Market by Distribution Channel
6.4.4.2 Argentina Uveitis Treatment Market
6.4.4.2.1 Argentina Uveitis Treatment Market by Drug Class
6.4.4.2.2 Argentina Uveitis Treatment Market by Disease Type
6.4.4.2.3 Argentina Uveitis Treatment Market by Distribution Channel
6.4.4.3 UAE Uveitis Treatment Market
6.4.4.3.1 UAE Uveitis Treatment Market by Drug Class
6.4.4.3.2 UAE Uveitis Treatment Market by Disease Type
6.4.4.3.3 UAE Uveitis Treatment Market by Distribution Channel
6.4.4.4 Saudi Arabia Uveitis Treatment Market
6.4.4.4.1 Saudi Arabia Uveitis Treatment Market by Drug Class
6.4.4.4.2 Saudi Arabia Uveitis Treatment Market by Disease Type
6.4.4.4.3 Saudi Arabia Uveitis Treatment Market by Distribution Channel
6.4.4.5 South Africa Uveitis Treatment Market
6.4.4.5.1 South Africa Uveitis Treatment Market by Drug Class
6.4.4.5.2 South Africa Uveitis Treatment Market by Disease Type
6.4.4.5.3 South Africa Uveitis Treatment Market by Distribution Channel
6.4.4.6 Nigeria Uveitis Treatment Market
6.4.4.6.1 Nigeria Uveitis Treatment Market by Drug Class
6.4.4.6.2 Nigeria Uveitis Treatment Market by Disease Type
6.4.4.6.3 Nigeria Uveitis Treatment Market by Distribution Channel
6.4.4.7 Rest of LAMEA Uveitis Treatment Market
6.4.4.7.1 Rest of LAMEA Uveitis Treatment Market by Drug Class
6.4.4.7.2 Rest of LAMEA Uveitis Treatment Market by Disease Type
6.4.4.7.3 Rest of LAMEA Uveitis Treatment Market by Distribution Channel

Chapter 7. Company Profiles
7.1 AbbVie, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals:
7.2 Alimera Sciences, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.1 Recent strategies and developments:
7.2.1.1 Product Launches and Product Expansions:
7.3 Enzo Biochem, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Research & Development Expense
7.4.4 Recent strategies and developments:
7.4.4.1 Product Launches and Product Expansions:
7.4.4.2 Partnerships, Collaborations, and Agreements:
7.5 Bausch Health Companies, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Clearside Biomedical, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Research & Development Expense
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 EyePoint Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.7.5.2 Acquisition and Mergers:
7.8 Santen Pharmaceutical Co., Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Topivert Ltd.
7.9.1 Company Overview
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Recent strategies and developments:
7.10.4.1 Acquisition and Mergers:
7.10.4.2 Approvals:
7.10.5 Research & Development Expense
Note: Product cover images may vary from those shown
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll